Industry

Dr. Papp: “The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options especially given the chronic nature of psoriasis which can necessitate long-term treatment.” Piclidenoson has a safety profile similar to placebo and is better tolerated than Otezla® Efficacy of Piclidenoson is similar … [Read more…]

TORONTO–(BUSINESS WIRE)–Mednow Inc. (“Mednow” or the “Company”) (TSXV:MNOW) (OTCQX:MDNWF), Canada’s on-demand virtual pharmacy, will participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022. The presentation will be available on demand at the H.C. Wainwright Conference Platform for 30 days. Mednow will be introducing its story to new potential investors and … [Read more…]

Confirmed single agent overall response rate of 43% and median duration of response of 17.8 months in MAPK-inhibitor naïve, V600+ population; 71% experienced clinical benefit of at least 24 weeks Responses observed in Primary CNS Tumors including both high grade and low grade gliomas FORE8394 is well-tolerated, with any adverse events being transient and manageable … [Read more…]

– Financing supports ongoing Phase 2b clinical trials of NDI-034858 (allosteric TYK2 inhibitor) and initiation of Phase 3; ongoing Phase 1/2 clinical trials of NDI-101150 (HPK1 inhibitor); and advancement of multiple preclinical programs – – Bain Capital Life Sciences and SV Health Investors participating as new investors – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company … [Read more…]

POTOMAC, Md.–(BUSINESS WIRE)–#IGC–India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on September 9, 2022 (the “Annual Meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 25, 2022, were passed by … [Read more…]

– Company to leverage expertise in mitochondrial biology to advance novel treatments for both rare and common diseases – – Pretzel founded by leading academic experts in mitochondrial biology and backed by world-class investor syndicate – – Platform technologies in gene correction, genome expression modulation, and mitochondrial quality control to enable wide variety of therapeutic … [Read more…]

TILs Engineered to Temporarily Express Membrane-Bound IL-2 and IL-12 Could Potentially Improve TIL Function While Simultaneously Eliminating the Need for Toxic Preconditioning and Cytokine Administration Data Presented at ESMO 2022 Show SQZ® TILs Enhanced Proliferation In Vitro and In Vivo, Increased Tumor Cell Killing, and Upregulated Markers Associated with T Cell Memory SQZ® TILs May … [Read more…]

SAILING INTO THE FUTURE. TOGETHER It’s a great emotion for IBSA, skipper Alberto Bona and the whole team of the international project Sailing into the Future. Together for this occasion, which officially kicks off the countdown to the Route du Rhum 2022, starting on November 6 from Saint-Malo. One month after the technical launch, Alberto … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “India Over The Counter Drug Market, By Product Type, By Route of Administration, By Dosage Form, By Distribution Channel, By Region, Competition, Forecast & Opportunities, 2018-2028F” report has been added to ResearchAndMarkets.com’s offering. India Over the Counter (OTC) Drug market stood at USD4666.15 Million in 2022 and is expected to grow at a … [Read more…]

Combined Company Dedicated to Developing and Delivering Novel Technologies and Solutions to Improve the Lives of Patients with Cardiac Arrhythmias Medtech Veteran David Jenkins to Lead Merged Company CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces it has entered into an Agreement and Plan of Merger (the “Definitive … [Read more…]